Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Other (2021 - 2023)

Zentalis Pharmaceuticals has reported Receivables - Other over the past 3 years, most recently at $7.9 million for Q1 2023.

  • For Q1 2023, Receivables - Other rose 236.8% year-over-year to $7.9 million; the TTM value through Mar 2023 reached $7.9 million, up 236.8%, while the annual FY2022 figure was $5.9 million, 147.53% up from the prior year.
  • Receivables - Other for Q1 2023 was $7.9 million at Zentalis Pharmaceuticals, up from $5.9 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $7.9 million in Q1 2023 and troughed at $2.3 million in Q1 2022.
  • A 3-year average of $4.1 million and a median of $3.1 million in 2022 define the central range for Receivables - Other.
  • Biggest five-year swings in Receivables - Other: skyrocketed 147.53% in 2022 and later skyrocketed 236.8% in 2023.
  • Year by year, Receivables - Other stood at $2.4 million in 2021, then skyrocketed by 147.53% to $5.9 million in 2022, then skyrocketed by 34.63% to $7.9 million in 2023.
  • Business Quant data shows Receivables - Other for ZNTL at $7.9 million in Q1 2023, $5.9 million in Q4 2022, and $3.2 million in Q3 2022.